Anthropic acquires biotech company Mithril Medicine

Anthropic has acquired Mithril Medicine, a Cambridge, Massachusetts, biotechnology company developing two early-stage antibodies for a rare form of muscular dystrophy that are not yet established treatments, Nature reported on 11 November 2026.

Mithril’s former chief executive, Cody Tranbarger, was its sole full-time employee and now works for Anthropic. Mithril also hired part-time consultants and paid at least five contract research organizations to conduct experiments.

How Mithril worked

Mithril used Anthropic’s superintelligence (SI) assistant Claude to help analyze data, suggest next steps and handle emails and paperwork involved in working with research contractors. The antibodies also depended on the work of human scientists.

Small biotech operations that outsource laboratory work predate such assistants. Entrepreneur Matt Davidson started his first biotech company in 2013 and kept only two full-time employees until its drug was ready for late-stage clinical testing; he said the company had no physical laboratory and contracted out all its lab work. Davidson said SI tools had made tiny biotechs more efficient, though he uses them mainly to summarize reports rather than for scientific discovery. He said his company uses consultants a little less than it used to.

Stanford University computer scientist James Zou expects SI to enable more small teams to identify opportunities and move quickly. Nature said many more researchers would be needed to advance Mithril’s drug development work, particularly if it eventually enters clinical trials.

Nature did not specify the acquisition date or price. Anthropic and Tranbarger declined to speak to the publication.